



(51) International Patent Classification:

C07K 16/46 (2006.01) A61K 39/395 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2022/070394

(22) International Filing Date:

28 January 2022 (28.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/146,334 05 February 2021 (05.02.2021) US
63/260,463 20 August 2021 (20.08.2021) US

(71) Applicant: PHANES THERAPEUTICS, INC. [US/US];
11535 Sorrento Valley Road; Suite 400, San Diego, CA
92121 (US).

(72) Inventors: LI, Jack, Chongyang; c/o Phanes Therapeutics,
Inc., 11535 Sorrento Valley Road; Suite 400, San Diego,
CA 92121 (US). JIA, Haiqun; c/o Phanes Therapeutics,
Inc., 11535 Sorrento Valley Road; Suite 400, San Diego,
CA 92121 (US). ZOU, Hui; c/o Phanes Therapeutics, Inc.,
11535 Sorrento Valley Road; Suite 400, San Diego, CA
92121 (US). WU, Huiwen; c/o Phanes Therapeutics, Inc.,

11535 Sorrento Valley Road; Suite 400, San Diego, CA
92121 (US). WANG, Minghan; c/o Phanes Therapeutics,
Inc., 11535 Sorrento Valley Road; Suite 400, San Diego,
CA 92121 (US).

(74) Agent: BARANIAK, Andrew P. et al.; Ice Miller
LLP, 1735 Market Street, Suite 3900, Philadelphia, PA
19103-7509 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: BISPECIFIC ANTIBODIES WITH CHARGE PAIRS AND USES THEREOF




FIG. 1

(57) Abstract: Engineered bispecific antibodies with charge pairs introduced at the interface of CHI and CL alone or in combination with other charge pairs at the interface of VH and VL are described. Also described are anti-CD47/anti-CLDN18.2 and anti-CD3/anti-DLL3 bispecific antibodies and antigen-binding fragments thereof. Also described are nucleic acids encoding the bispecific antibodies, compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies and using the bispecific antibodies for treating or preventing diseases, such as cancer and/or associated complications.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*